CY2013028I1 - Ουρικη οξειδαση ελευθερη συσσωματωματων για την παρασκευη μη ανοσογονων συζευγματων με πολυμερες - Google Patents

Ουρικη οξειδαση ελευθερη συσσωματωματων για την παρασκευη μη ανοσογονων συζευγματων με πολυμερες

Info

Publication number: CY2013028I1
Authority: CY; Cyprus
Prior art keywords: uric; polymers; oxidation; preparation; immune conjugates
Prior art date: 2000-02-10

Application number

CY2013028C

Other languages

English (en)

Other versions

CY2013028I2 (el

Original Assignee

Mountain View Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-10

Filing date

2013-07-04

Publication date

2015-11-04

2013-07-04 Application filed by Mountain View Pharmaceuticals Inc filed Critical Mountain View Pharmaceuticals Inc

2015-11-04 Publication of CY2013028I2 publication Critical patent/CY2013028I2/el

2015-11-04 Publication of CY2013028I1 publication Critical patent/CY2013028I1/el

Links

LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title 1
230000003647 oxidation Effects 0.000 title 1
238000007254 oxidation reaction Methods 0.000 title 1
229920000642 polymer Polymers 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CY2013028C 2000-02-10 2013-07-04 Ουρικη οξειδαση ελευθερη συσσωματωματων για την παρασκευη μη ανοσογονων συζευγματων με πολυμερες CY2013028I1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/501,730 US6783965B1 (en)	2000-02-10	2000-02-10	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (en)	2000-02-10	2001-02-07	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (2)

Publication Number	Publication Date
CY2013028I2 CY2013028I2 (el)	2015-11-04
CY2013028I1 true CY2013028I1 (el)	2015-11-04

Family

ID=23994789

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20101100597T CY1110142T1 (el)	2000-02-10	2010-06-29	Ουρικη οξειδαση ελευθερη συσσωματωματων για την παρασκευη μη ανοσογονων συζευγματων με πολυμερες
CY2013028C CY2013028I1 (el)	2000-02-10	2013-07-04	Ουρικη οξειδαση ελευθερη συσσωματωματων για την παρασκευη μη ανοσογονων συζευγματων με πολυμερες
CY20151100129T CY1117264T1 (el)	2000-02-10	2015-02-09	Συζευγματα παρασκευαζομενα με πρωτεϊνες ελευθερες συσσωματωματων

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20101100597T CY1110142T1 (el)	2000-02-10	2010-06-29	Ουρικη οξειδαση ελευθερη συσσωματωματων για την παρασκευη μη ανοσογονων συζευγματων με πολυμερες

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY20151100129T CY1117264T1 (el)	2000-02-10	2015-02-09	Συζευγματα παρασκευαζομενα με πρωτεϊνες ελευθερες συσσωματωματων

Country Status (28)

Country	Link
US (3)	US6783965B1 (el)
EP (3)	EP2196538B1 (el)
JP (2)	JP5165826B2 (el)
KR (3)	KR101054247B1 (el)
CN (2)	CN100491532C (el)
AT (1)	ATE463576T1 (el)
AU (3)	AU4997501A (el)
BE (1)	BE2013C045I2 (el)
BR (1)	BRPI0108386B8 (el)
CA (1)	CA2398679C (el)
CY (3)	CY1110142T1 (el)
CZ (1)	CZ304864B6 (el)
DE (1)	DE60141742D1 (el)
DK (3)	DK2196538T3 (el)
ES (2)	ES2343105T3 (el)
FR (1)	FR13C0036I2 (el)
HK (4)	HK1056742A1 (el)
HU (1)	HU227127B1 (el)
IL (3)	IL151065A0 (el)
LU (1)	LU92237I2 (el)
MX (1)	MXPA02007545A (el)
NZ (1)	NZ520434A (el)
PL (1)	PL208064B1 (el)
PT (2)	PT1254237E (el)
RU (3)	RU2352354C2 (el)
TW (2)	TW200914617A (el)
WO (1)	WO2001059078A2 (el)
ZA (1)	ZA200207206B (el)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JP5183836B2 (ja) *	1998-08-06	2013-04-17	マウンテンビューファーマシューティカルズ，インコーポレイテッド	Ｐｅｇ−尿酸酸化酵素結合体およびその使用
US20060188971A1 (en) *	1998-08-06	2006-08-24	Duke University	Urate oxidase
PT1100880E (pt)	1998-08-06	2011-01-13	Univ Duke	Urato-oxidase
US6783965B1 (en)	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2338665C (en)	1998-08-06	2011-01-18	Mountain View Pharmaceuticals, Inc.	Peg-urate oxidase conjugates and use thereof
US7229810B2 (en)	2001-06-28	2007-06-12	Mountain View Pharmaceuticals, Inc.	Polymer conjugates of proteinases
US6913915B2 (en) *	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
EP2298278B1 (en)	2002-06-07	2015-11-11	Dyax Corp.	Prevention and reduction of blood loss and inflammatory response
US20040062748A1 (en)	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) *	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050502A (en) *	2002-12-26	2007-08-03	Mountain View Pharmaceuticals Inc.,	Polymer conjugates of interferon- beta with enhanced biological potency
WO2004101600A2 (en) *	2003-05-12	2004-11-25	Affymax, Inc.	Novel poly(ethylene glycol) modified compounds and uses thereof
ES2395413T3 (es) *	2003-05-12	2013-02-12	Affymax, Inc.	Péptidos que se unen al receptor de eritropoyetina
MXPA05012314A (es) *	2003-05-12	2006-04-18	Affymax Inc	Radical separador para peptido modificado con polietilenglicol.
CA3050564A1 (en) *	2003-08-29	2005-03-10	Dyax Corp.	Poly-pegylated protease inhibitors
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP2008519858A (ja) *	2004-11-11	2008-06-12	アフィーマックス・インコーポレイテッド	エリスロポエチンレセプターに結合する新規ペプチド
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
CA2602654A1 (en) *	2005-04-05	2006-10-12	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Method for shielding functional sites or epitopes on proteins
US8148123B2 (en) *	2005-04-11	2012-04-03	Savient Pharmaceuticals, Inc.	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) *	2005-04-11	2008-07-03	Jacob Hartman	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
ES2856881T3 (es)	2005-04-11	2021-09-28	Horizon Pharma Rheumatology Llc	Formas variantes de urato oxidasa y su uso
EP1871877A2 (en)	2005-04-11	2008-01-02	Savient Pharmaceuticals, Inc.	A variant form of urate oxidase and use thereof
EP1883425A1 (en) *	2005-05-23	2008-02-06	Universite De Geneve	Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US7550433B2 (en) *	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
ES2532804T3 (es) *	2006-04-12	2015-03-31	Crealta Pharmaceuticals Llc	Purificación de proteínas con tensioactivo catiónico
CA2696208A1 (en) *	2007-08-21	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
AU2010203712A1 (en)	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
AU2010265964B2 (en)	2009-06-25	2014-09-18	Horizon Therapeutics Usa, Inc.	Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
LT2521568T (lt)	2010-01-06	2018-12-10	Dyax Corp.	Plazmos kalikreiną surišantys baltymai
US8940861B2 (en)	2010-04-08	2015-01-27	Georgia Tech Research Corporation	Variants of ancestral uricases and uses thereof
BR112013017080A8 (pt)	2011-01-06	2023-05-09	Dyax Corp	Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
CN102827073A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
DK3003358T3 (da)	2013-06-07	2021-06-21	Allena Pharmaceuticals Inc	Sammensætninger og anordninger til dialyse
CA2917671A1 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en)	2013-07-11	2017-02-28	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
WO2015003360A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
WO2015003355A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
US20150031627A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
US9968595B2 (en)	2014-03-14	2018-05-15	Agios Pharmaceuticals, Inc.	Pharmaceutical compositions of therapeutically active compounds
US10428158B2 (en)	2014-03-27	2019-10-01	Dyax Corp.	Compositions and methods for treatment of diabetic macular edema
EP3294322A4 (en)	2015-05-15	2018-12-12	Medimmune, LLC	Improved uricase sequences and methods of treatment
MX2018004587A (es)	2015-10-15	2018-08-14	Agios Pharmaceuticals Inc	Terapia de combinacion para tratar tumores malignos.
KR20180067658A (ko)	2015-10-15	2018-06-20	아지오스 파마슈티컬스 아이엔씨.	악성 종양의 치료를 위한 조합물 요법
BR112018011622A2 (pt)	2015-12-11	2018-11-27	Dyax Corp	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
US20230085022A1 (en)	2016-11-11	2023-03-16	Horizon Therapeutics Usa, Inc.	Combination therapies of prednisone and uricase molecules and uses thereof
JP2020530282A (ja)	2017-07-07	2020-10-22	アレナファーマシューティカルズ，インコーポレイテッド	組換えウリカーゼ酵素
US20190309269A1 (en)	2018-03-20	2019-10-10	Rubius Therapeutics, Inc.	Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
CN109055260B (zh) *	2018-08-08	2021-11-09	淮海工学院	弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
CN114181917B (zh) *	2022-02-14	2022-06-03	潍坊华卓生物科技有限公司	一种改造尿酸酶、基因序列、制备方法及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE279486C (el)
US3616231A (en)	1968-11-14	1971-10-26	Boehringer Mannheim Gmbh	Process for the production of uricase
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5599189A (en)	1979-01-22	1980-07-28	Mihama Hisaharu	Modified uricase free from antigenicity and its preparation
JPS55135590A (en)	1979-04-05	1980-10-22	Mihama Hisaharu	Modified asparaginase and uricase and their preparation
CH657141A5 (de)	1980-07-01	1986-08-15	Hoffmann La Roche	Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS57192435A (en)	1981-05-20	1982-11-26	Toyobo Co Ltd	Modified polypeptide
DE3126759A1 (de)	1981-07-07	1983-01-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
WO1987000056A1 (en) *	1985-06-26	1987-01-15	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) *	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de)	1986-03-10	1990-06-06	Akad Wissenschaften Ddr	Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) *	1986-04-23	1987-03-10	Mihama Hisaharu	修飾ウリカ−ゼ
JPH085506B2 (ja) *	1986-08-25	1996-01-24	日東製器株式会社	缶容器
DD279489A1 (de)	1986-12-11	1990-06-06	Leuna Werke Veb	Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) *	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en)	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
US5955336A (en) *	1988-08-17	1999-09-21	Toyo Boseki Kabushiki Kaisha	DNA sequence for uricase and manufacturing process of uricase
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) *	1989-07-13	1993-01-27	Sanofi Sa	Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en)	1989-07-13	1995-01-17	Sanofi	Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en)	1989-08-07	1994-02-15	Debiopharm, S.A.	Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja)	1989-11-01	1991-06-25	Sumitomo Pharmaceut Co Ltd	修飾ペプチドおよびその製造方法
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US5653974A (en)	1990-10-18	1997-08-05	Board Of Regents,The University Of Texas System	Preparation and characterization of liposomal formulations of tumor necrosis factor
WO1992016221A1 (en) *	1991-03-15	1992-10-01	Synergen, Inc.	Pegylation of polypeptides
DE69233690T2 (de)	1991-07-02	2008-01-24	Nektar Therapeutics, San Carlos	Abgabevorrichtung für nebelförmige Medikamente
AU6240494A (en)	1993-02-16	1994-09-14	Enzon, Inc.	Ribosome inactivating protein compositions having reduced antigenicity
AU6586394A (en) *	1993-04-22	1994-11-08	Celtrix Pharmaceuticals, Inc.	Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en)	1993-06-21	1995-01-05	Enzon, Inc.	Site specific synthesis of conjugated peptides
IT1265101B1 (it) *	1993-07-23	1996-10-30	Erba Carlo Spa	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5919455A (en)	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
DK0730470T3 (da) *	1993-11-10	2002-06-03	Enzon Inc	Forbedrede interferonpolymerkonjugater
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
WO1996017929A1 (en) *	1994-12-07	1996-06-13	Novo Nordisk A/S	Polypeptide with reduced allergenicity
US5932462A (en) *	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) *	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	インターフェロンを含む液体製剤
FR2733914B1 (fr) *	1995-05-11	1997-08-01	Sanofi Sa	Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en)	1995-06-07	1998-12-29	Chiron Corporation	Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja)	1995-12-05	1997-06-17	Asahi Chem Ind Co Ltd	ウリカーゼを生産する実質上純粋な微生物
EP1007082B1 (en)	1997-01-15	2006-10-18	Phoenix Pharmacologics, Inc.	Modified tumor necrosis factor
EP1500661A1 (en) *	1998-06-01	2005-01-26	Genetech, Inc.	Separation of protein monomers from aggregates by use of ion-exchange chromatography
PT1100880E (pt)	1998-08-06	2011-01-13	Univ Duke	Urato-oxidase
CA2338665C (en) *	1998-08-06	2011-01-18	Mountain View Pharmaceuticals, Inc.	Peg-urate oxidase conjugates and use thereof
JP5183836B2 (ja)	1998-08-06	2013-04-17	マウンテンビューファーマシューティカルズ，インコーポレイテッド	Ｐｅｇ−尿酸酸化酵素結合体およびその使用
US6783965B1 (en) *	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6425448B1 (en)	2001-01-30	2002-07-30	Cdx Gas, L.L.P.	Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) *	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
WO2014187953A1 (en)	2013-05-24	2014-11-27	Zentrum Mikroelektronik Dresden Ag	Non pwm digital dc-dc converter

2000
- 2000-02-10 US US09/501,730 patent/US6783965B1/en not_active Expired - Lifetime
2001
- 2001-02-06 TW TW097145974A patent/TW200914617A/zh unknown
- 2001-02-06 TW TW090102540A patent/TWI322184B/zh not_active IP Right Cessation
- 2001-02-07 EP EP10158016.5A patent/EP2196538B1/en not_active Expired - Lifetime
- 2001-02-07 AU AU4997501A patent/AU4997501A/xx active Pending
- 2001-02-07 CA CA2398679A patent/CA2398679C/en not_active Expired - Lifetime
- 2001-02-07 PL PL358539A patent/PL208064B1/pl unknown
- 2001-02-07 ES ES01923265T patent/ES2343105T3/es not_active Expired - Lifetime
- 2001-02-07 CN CNB018077501A patent/CN100491532C/zh not_active Expired - Lifetime
- 2001-02-07 DK DK10158016.5T patent/DK2196538T3/en active
- 2001-02-07 DE DE60141742T patent/DE60141742D1/de not_active Expired - Lifetime
- 2001-02-07 RU RU2006107110/13A patent/RU2352354C2/ru active
- 2001-02-07 CZ CZ2002-2982A patent/CZ304864B6/cs not_active IP Right Cessation
- 2001-02-07 JP JP2001558218A patent/JP5165826B2/ja not_active Expired - Lifetime
- 2001-02-07 KR KR1020087024272A patent/KR101054247B1/ko active IP Right Grant
- 2001-02-07 PT PT01923265T patent/PT1254237E/pt unknown
- 2001-02-07 KR KR1020027010189A patent/KR100884724B1/ko active IP Right Grant
- 2001-02-07 WO PCT/US2001/040069 patent/WO2001059078A2/en active Application Filing
- 2001-02-07 IL IL15106501A patent/IL151065A0/xx unknown
- 2001-02-07 BR BRPI0108386A patent/BRPI0108386B8/pt not_active Application Discontinuation
- 2001-02-07 RU RU2002120486/13A patent/RU2281954C2/ru not_active IP Right Cessation
- 2001-02-07 AU AU2001249975A patent/AU2001249975B2/en not_active Revoked
- 2001-02-07 CN CN2009101278530A patent/CN101735991B/zh not_active Expired - Lifetime
- 2001-02-07 DK DK10180428.4T patent/DK2305819T3/en active
- 2001-02-07 MX MXPA02007545A patent/MXPA02007545A/es active IP Right Grant
- 2001-02-07 DK DK01923265.1T patent/DK1254237T3/da active
- 2001-02-07 EP EP10180428.4A patent/EP2305819B1/en not_active Expired - Lifetime
- 2001-02-07 AT AT01923265T patent/ATE463576T1/de active
- 2001-02-07 HU HU0204544A patent/HU227127B1/hu active Protection Beyond IP Right Term
- 2001-02-07 EP EP01923265A patent/EP1254237B1/en not_active Expired - Lifetime
- 2001-02-07 PT PT101804284T patent/PT2305819E/pt unknown
- 2001-02-07 KR KR1020077018682A patent/KR20070092329A/ko active Search and Examination
- 2001-02-07 ES ES10180428.4T patent/ES2524153T3/es not_active Expired - Lifetime
- 2001-02-07 NZ NZ520434A patent/NZ520434A/en not_active IP Right Cessation
2002
- 2002-08-05 IL IL151065A patent/IL151065A/en active Protection Beyond IP Right Term
- 2002-09-09 ZA ZA200207206A patent/ZA200207206B/en unknown
2003
- 2003-12-11 HK HK03109064.9A patent/HK1056742A1/xx not_active IP Right Cessation
2007
- 2007-08-03 US US11/882,750 patent/US7927852B2/en not_active Expired - Fee Related
2008
- 2008-08-11 IL IL193365A patent/IL193365A/en active IP Right Grant
2009
- 2009-02-06 RU RU2009104003/10A patent/RU2557318C9/ru active
- 2009-09-02 AU AU2009212900A patent/AU2009212900B2/en not_active Expired
2010
- 2010-06-29 CY CY20101100597T patent/CY1110142T1/el unknown
- 2010-10-27 HK HK10110105.9A patent/HK1143989A1/xx not_active IP Right Cessation
- 2010-10-27 HK HK11109405.7A patent/HK1155203A1/xx not_active IP Right Cessation
- 2010-12-08 HK HK10111402.7A patent/HK1144701A1/xx not_active IP Right Cessation
2011
- 2011-04-12 JP JP2011088663A patent/JP5341945B2/ja not_active Expired - Lifetime
- 2011-04-13 US US13/085,793 patent/US8921064B2/en not_active Expired - Fee Related
2013
- 2013-07-03 BE BE2013C045C patent/BE2013C045I2/fr unknown
- 2013-07-03 LU LU92237C patent/LU92237I2/fr unknown
- 2013-07-04 FR FR13C0036C patent/FR13C0036I2/fr active Active
- 2013-07-04 CY CY2013028C patent/CY2013028I1/el unknown
2015
- 2015-02-09 CY CY20151100129T patent/CY1117264T1/el unknown

Also Published As

Publication number	Publication date
KR101054247B1 (ko)	2011-08-08
PT2305819E (pt)	2015-06-01
JP2011188861A (ja)	2011-09-29
HK1056742A1 (en)	2004-02-27
CN1423699A (zh)	2003-06-11
HK1144701A1 (en)	2011-03-04
EP2305819A1 (en)	2011-04-06
JP5341945B2 (ja)	2013-11-13
JP2003521937A (ja)	2003-07-22
HUP0204544A2 (en)	2003-05-28
ES2343105T3 (es)	2010-07-23
HK1143989A1 (en)	2011-01-21
PL358539A1 (en)	2004-08-09
RU2281954C2 (ru)	2006-08-20
DK2305819T3 (en)	2015-01-05
US6783965B1 (en)	2004-08-31
BR0108386B1 (pt)	2017-10-31
EP2196538B1 (en)	2014-10-01
DK1254237T3 (da)	2010-07-19
ATE463576T1 (de)	2010-04-15
US20080057048A1 (en)	2008-03-06
BR0108386A (pt)	2002-10-29
AU2001249975B2 (en)	2006-06-08
CA2398679A1 (en)	2001-08-16
HUP0204544A3 (en)	2007-05-02
RU2352354C2 (ru)	2009-04-20
MXPA02007545A (es)	2002-12-13
JP5165826B2 (ja)	2013-03-21
LU92237I2 (fr)	2013-09-03
FR13C0036I1 (fr)	2013-08-09
EP2196538A1 (en)	2010-06-16
PT1254237E (pt)	2010-06-07
WO2001059078A3 (en)	2002-03-07
RU2557318C9 (ru)	2015-09-10
KR20020087934A (ko)	2002-11-23
RU2557318C2 (ru)	2015-07-20
US20110287466A1 (en)	2011-11-24
BE2013C045I2 (el)	2020-06-24
CZ304864B6 (cs)	2014-12-17
IL193365A0 (en)	2009-02-11
DK2196538T3 (en)	2015-01-05
CN100491532C (zh)	2009-05-27
HU227127B1 (en)	2010-07-28
CA2398679C (en)	2015-11-17
KR20080098686A (ko)	2008-11-11
AU2009212900A1 (en)	2009-10-01
AU4997501A (en)	2001-08-20
ES2343105T8 (es)	2013-07-15
HK1155203A1 (en)	2012-05-11
AU2009212900B2 (en)	2011-12-08
ZA200207206B (en)	2003-05-06
ES2524153T3 (es)	2014-12-04
DE60141742D1 (de)	2010-05-20
CZ20022982A3 (cs)	2003-01-15
KR100884724B1 (ko)	2009-02-19
CN101735991A (zh)	2010-06-16
CY2013028I2 (el)	2015-11-04
BRPI0108386B8 (pt)	2021-05-25
RU2006107110A (ru)	2007-09-20
PL208064B1 (pl)	2011-03-31
CY1110142T1 (el)	2015-01-14
FR13C0036I2 (fr)	2014-05-16
TW200914617A (en)	2009-04-01
CN101735991B (zh)	2013-09-11
TWI322184B (en)	2010-03-21
US8921064B2 (en)	2014-12-30
US7927852B2 (en)	2011-04-19
KR20070092329A (ko)	2007-09-12
IL151065A (en)	2008-12-29
EP1254237B1 (en)	2010-04-07
IL151065A0 (en)	2003-04-10
EP2305819B1 (en)	2014-11-12
IL193365A (en)	2011-08-31
WO2001059078A2 (en)	2001-08-16
BR0108386C1 (pt)	2011-12-20
CY1117264T1 (el)	2017-04-26
NZ520434A (en)	2004-05-28
EP1254237A2 (en)	2002-11-06
RU2009104003A (ru)	2010-08-20

Publication	Publication Date	Title
CY2013028I2 (el)	2015-11-04	Ουρικη οξειδαση ελευθερη συσσωματωματων για την παρασκευη μη ανοσογονων συζευγματων με πολυμερες
MA25850A1 (fr)	2003-07-01	Conjugues de pro-parfums photolabiles.
DE60031785D1 (de)	2006-12-21	Lenkbarer katheter
DK1216184T3 (da)	2013-03-25	Køretøj med drivkraft-assistance
DE60006649D1 (de)	2003-12-24	C-21 modifizierte epothilone
DE60119503D1 (de)	2006-06-14	Lenkmechanismus
NO20000924L (no)	2000-08-28	Brønnforing med ens diameter
NO20042140L (no)	2004-07-22	Terapeutiske quionolonforbindelser med 5-HT anatagonistiske egenskaper
DE60018813D1 (de)	2005-04-28	Reifen mit hervorragender Lenkungstabilität
DE60036967D1 (de)	2007-12-13	Kunstharzpalette
EE200200169A (et)	2003-04-15	Terapeutiliselt väärtuslike omadustega indolüül-3-glüoksüülhappe derivaadid
FR2812476B1 (fr)	2002-10-31	Convertisseur alternatif-continu
DE60137941D1 (de)	2009-04-23	Polymerzusammensetzung
DE60032946D1 (de)	2007-02-22	Katheter
NO20013440L (no)	2001-09-11	Sammensetninger med forbedret stabilitet
PT1165495E (pt)	2005-08-31	Derivados de resorcinol
DE50104469D1 (de)	2004-12-16	Lenkrad
ATE288940T1 (de)	2005-02-15	Polymerzusammensetzung
DE50104709D1 (de)	2005-01-05	Sattelkupplung
DK1263914T3 (da)	2010-06-28	Klæbemiddelsammensætning med øget hærdningsrate
AR028091A1 (es)	2003-04-23	Combinaciones de agentes fitoprotectores con polimeros anionicos
DE60021984D1 (de)	2005-09-22	Momentwandler
DE60112018D1 (de)	2005-08-25	Lenkrad
AR028092A1 (es)	2003-04-23	Combinaciones de agentes fitoprotectores con polimeros cationicos
EE200300081A (et)	2005-02-15	Elektriõhuliini masti ülaosas paiknev elektriõhuliini kinnituskonstruktsioon